PDS Biotechnology Announces Collaboration – GuruFocus.com

0

FLORHAM PARK, NJ, July 26, 2022 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (PDSB), a clinical-stage immunotherapy company developing a growing pipeline of molecularly targeted cancer immunotherapies and infectious disease vaccines based on the company’s Versamune® and Infectimune™ T Cell Activation Technologies announced today that the Company will report second quarter 2022 financial results on Monday, August 8, 2022, prior to market open. Post release, management will host a conference call to review financial results and provide a business update.

Monday, August 8, 2022 at 8:00 a.m. EDT
Domestic: 877-407-3088
International: 201-389-0927
Conference ID: 13731437
web cast: PDS Biotech Earnings Webcast

The event will be archived on PDS Biotech’s website for six months following the live webcast.

About PDS Biotechnology
PDS Biotech is a clinical-stage immunotherapy company developing a growing pipeline of molecularly targeted immunotherapies for cancer and infectious diseases based on the company’s Versamune® and Infectimune™ T-cell activating technology platforms. We believe our Versamune® based products have shown the potential to overcome the limitations of current induction-based immunotherapy in vivo, large quantities of high-quality, highly potent polyfunctional tumor-specific CD4+ helper and CD8+ killer T cells. PDS Biotech has developed several therapies based on combinations of Versamune® and disease-specific antigens, designed to train the immune system to better recognize diseased cells and effectively attack and destroy them. The Company continues to expand its pipeline of preclinical and clinical candidates to treat a broad spectrum of cancers, including HPV16-associated cancers (anal, cervical, head and neck, penile, vaginal, vulvar) and breast -, colon, lung, prostate and ovarian cancer.

Our Infectimune™-based vaccines have demonstrated the potential to induce not only robust and durable neutralizing antibody responses, but also potent T cell responses, including long-lasting memory T cell responses. To learn more, please visit www.pdsbiotech.com or follow us on Twitter at @PDSBiotech.

Versamune® is a registered trademark and Infectimune™ is a trademark of PDS Biotechnology Corporation.

Investor contact:
Rich Cockrell
CG capital
Telephone: +1 (404) 736-3838
[email protected]

PDS-Biotechnology-Corporation.png

Share.

Comments are closed.